1. The study evaluated patients who had surgery with the device for symptomatic degenerative disc disease and spinal stenosis.
2. Analyses of the patients at six-months found sustained improvement in clinical efficacy and safety compared to three-month evaluations.
3. Reserachers concluded, “This 6-month interim analysis at 42% enrollment of patients was conducted to determine prolonged safety and efficacy of the interspinous fusion device. Our analysis showed a sustained improvement in clinical efficacy, and safety endpoints, when compared to the 3-months evaluations, across both interventional pain and neurosurgery specialties.”
4. The Zip system was cleared by the FDA inn 2013 and went to market in 2014.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
